Innate Pharma

Orega Biotech

Schering Corporation

Centre Leon Berard

Orega Biotech Sas

Carine Paturel

Laurent Gauthier

Mathieu Blery

Ivan Perrot

Benjamin Rossi

Pascale Andre

Hélène Sicard

Yannis Morel

Nicolai Wagtmann

Nadia Anceriz

Simon Kollnberger

Stéphanie Zerbib

Agnes Tisserant

Christophe Caux

Christian Belmant

Christine Menetrier-Caux

Delphine Bregeon

Nicolas Gourdin

Stéphanie Chanteux

Stéphanie Cornen

Caroline Soulas

Karine Chemin

Helene Sicard

Cecile Bonnafous

Cécile Bonnafous

Jean-Jacques Pin

Giorgio Trinchieri

Arnaud Dujardin

Hatem Abdelazim

Nicolaï Wagtmann

Catherine Massacrier

Eric Aubin

Caroline Denis

Christine Menetrier-caux

Stephanie Zerbib

Stephanie Cornen

Agnès Tisserant

The present invention relates to methods for the treatment of T cell lymphomas using compounds that specifically bind KIR3DL2 in combination with chemotherapeutic agents, notably gemcitabine and/or oxaliplatin. The treatments are particularly useful in the treatment of peripheral T cell lymphomas, for example PTCL-NOS.

Treatment of T cell lymphoma

The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

NKp46 binding agents

The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

Nucleic acids encoding and methods of producing proteins comprising antibody chains

The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

Treatment regimens using anti-NKG2A antibodies

This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

Treatment with anti-KIR3DL2 agents

This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

CD73 blockade

The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

KIR3DL2 binding agents

Compositions and methods for treating cancer

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

Neutralization of inhibitory pathways in lymphocytes

Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide

Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.

CD73 blocking agents

This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.

This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5' nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.

Methods for detecting tissue infiltrating NK cells

Growing community of inventors

Marcy l'Etoile, France

Carine Paturel